Predictive Value of <i>SLCO1B1</i> c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users
Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening i...
Main Authors: | Marleen E. Jansen, Tessel Rigter, Thom M. C. Fleur, Patrick C. Souverein, W. M. Monique Verschuren, Susanne J. Vijverberg, Jesse J. Swen, Wendy Rodenburg, Martina C. Cornel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/14/2/456 |
Similar Items
-
<i>SLCO1B1</i> Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia
by: Jonathan B. Wagner, et al.
Published: (2024-01-01) -
Clinical case of statin-induced myopathy in female patient with compensated hypothyroidism and unfavorable polymorphic variant of SLCO1B1*5 (c.521T>C)
by: Liya A. Lugovaya, et al.
Published: (2021-05-01) -
Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity
by: Marleen E. Jansen, et al.
Published: (2017-08-01) -
<i>CYP3A5*3</i> and <i>SLCO1B1</i> c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
by: Jin-Woo Park, et al.
Published: (2022-07-01) -
Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn’s disease
by: E.J. Laserna-Mendieta, et al.
Published: (2023-03-01)